Device Trial Radar · NCT07204678
PMCF Study of Precise Pro Rx for Carotid Artery Disease
Last checked: Nov 20, 2026Latest source record: Mar 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
199
Actual
Start
Oct 30, 2025
Primary completion
Feb 27, 2026
Study completion Feb 27, 2026
Sponsor
- Lead sponsor
- Cordis US Corp.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Rede Optimus Hospitalar SA
- First posted
- Oct 2, 2025
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate long-term clinical safety and performance of the PRECISE PRO RX Nitinol Stent System to treat stenotic lesions of the carotid arteries.
Conditions
- Carotid Artery Stenosis
Interventions
PRECISE PRO Rx Nitinol Stent SystemDevice
The Cordis PRECISE PRO Rx Nitinol Stent System is a single-use device consisting of an endovascular stent and sheath delivery system, intended to deliver a self-expanding endovascular stent to the carotid artery(ies). The stent component imparts an outward radial force on the luminal surface of the vessel wall restoring vascular patency. The Cordis PRECISE PRO Rx Nitinol Stent System is indicated for use in patients with stenotic lesions of the carotid artery(ies).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Performance Endpoint - Technical SuccessTime frame: At the conclusion of the index procedure
6 more outcomes with a free account
Locations
4 sites in 3 countries. Site status is shown where the registry gives one.
University Hospital Tulln
Tulln, Austria
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.